Brief: Interim Review Of Proprietary PsiGAD Clinical Trial Data Indicates No Safety Concerns
15/03/2023 11:37
March 15 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INTERIM REVIEW OF PROPRIETARY PSIGAD CLINICAL TRIAL DATA
INDICATES NO SAFETY CONCERNS AND PROJECTS A STATISTICALLY
SIGNIFICANT BENEFIT FOR THE PSILOCYBIN ARM VERSUS THE PLACEBO
ARM IN THOSE PARTICIPANTS WHO HAVE COMPLETED THE TREATMENT
* INCANNEX HEALTHCARE LTD - TRIAL TEAM AND DSMB HAVE
IDENTIFIED NO
SAFETY CONCERNS TO DATE
* INCANNEX HEALTHCARE LTD - TREATMENT OF ALL 72 TRIAL
PARTICIPANTS
IS ANTICIPATED TO BE COMPLETED IN Q4 OF 2023
Source text for Eikon: ID:nGNX7NyGvN
Further company coverage: IHL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed